After hitting primary endpoint, Axsome planning second trial in Alzheimer’s agitation

Already headed for an FDA submission this year in depression, Axsome’s multimodal NMDA receptor agonist now has pivotal data for a second indication: agitation associated with Alzheimer’s disease.

New data showing that AXS-05 significantly improved agitation symptoms in a Phase II/III trial drove shares of Axsome Therapeutics Inc. (NASDAQ:AXSM) up $18.60 (24%) to $95 Monday, briefly peaking intraday within a dollar of their all-time high of $109.94. Axsome added more than $650 million in market cap with the move...